Praxis share price halved after essential tremor fail, but biotech still plans phase 3

Praxis Precision Medicines isn’t letting a midphase fail stand in the way of its plans in essential tremor. While its selective T-type calcium channel blocker failed to beat placebo on the primary endpoint, Praxis zeroed in on secondary measures and post hoc analyses to make the case for further development.